FIELD: medicine, pharmaceutics.
SUBSTANCE: there is offered application of 5'-methylthyoadenosine (MTA), or its pharmaceutically acceptable salt, a prodrug for preparing a medicine for treating an autoimmune diseases where said medicine delays the beginning of outbreaks in an individual suffering multiple sclerosis (MS), or slows down the progression of MS (progressing phase) in an individual suffering MS, and a related method.
EFFECT: MTA delays the beginning of development of the second outbreak of MS and ensures higher survival percentage.
8 cl, 6 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEINKINASE C INHIBITORS USED FOR TREATING AUTOIMMUNE DISEASES AND GRAFT REJECTION | 2005 |
|
RU2413511C2 |
| PEPTIDE FROM THE COMPOSITION OF THE IMMUNOGLOBULIN HUMAN HEAVY CHAIN, SUITABLE FOR TREATMENT OF MULTIPLE SCLEROSIS | 2016 |
|
RU2646817C1 |
| MAIN FATTY ACID ETHERS AND THEIR APPLICATION AS ANTI-INFLAMMATION OR IMMUNOMODULATORY MEDICATIONS | 2003 |
|
RU2337093C2 |
| MACROLIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | 2002 |
|
RU2321402C2 |
| METHOD OF ACTIVATION OF REGULATORY T-CELLS OF ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | 2011 |
|
RU2599495C2 |
| PEPTIDE CONJUGATED PARTICLES | 2013 |
|
RU2669346C2 |
| PEPTIDE | 2014 |
|
RU2675479C2 |
| LIPOSOMES CONTAINING OLIGOPEPTIDE FRAGMENTS OF MYELIN BASIC PROTEIN, PHARMACEUTICAL COMPOSITION AND METHOD FOR MULTIPLE SCLEROSIS TREATMENT | 2013 |
|
RU2639497C2 |
| AGENTS SUPPRESSING REJECTION OF TRANSPLANT | 2002 |
|
RU2263512C2 |
| ACTH-LIKE PEPTIDE WITH IMMUNOSUPRESSOR FUNCTION | 2017 |
|
RU2681317C1 |
